Results 61 to 70 of about 23,963 (194)

Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study

Iranian Journal of Allergy, Asthma and Immunology, 2018
Fingolimod is a novel immunomodulatory drug used in patients with relapsing multiple sclerosis (MS) which reversibly inhibits egress of lymphocytes from lymph nodes. In this longitudinal study, the frequency of Interferon- gamma (IFN-γ)+, IL4+, IL17+ and
Bahare Laribi, Mohammad Ali Sahraian, Mehdi Shekarabi, Rahimeh Emamnejad, Mohsen Marzban, Shokufeh Sadaghiani, Maryam Izad   +6 more
doaj   +1 more source

Post-ischaemic immunological response in the brain: targeting microglia in ischaemic stroke therapy [PDF]

, 2020
Microglia, the major endogenous immune cells of the central nervous system, mediate critical degenerative and regenerative responses in ischaemic stroke.
Chen, Ruoli, Dallas, Mark L., Jenkins, Stuart, Rawlinson, Charlotte, Thei, Laura   +4 more
core   +3 more sources

Discovery of an Adaptive Neuroimmune Response Driving Itch and Fast Tick Removal with Implications for Preventing Pathogen Transmission

Advanced Science, EarlyView.
Itch‐induced tick removal (IITR): An acquired neuroimmune mechanism, itch‐induced tick removal, develops after repeated tick exposure, mobilizing T cells and macrophages at the tick bite site to trigger a rapid scratching response that facilitates timely tick removal within a critical window that preces the transmission of many tick‐borne pathogens ...
Johannes S. P. Doehl, Tiago D. Serafim, Serena Doh, Charles S. Grugan, Eva Iniguez, Luana Rogerio, Ronja Frigard, Ranadhir Dey, Pedro Cecilio, Xinglong Gu, Pang‐Yen Tseng, Aline da Silva Moreira, Mahnaz Minai, James Oristian, Hans Ackerman, Steven Brooks, Caroline Percopo, Siu‐Ping Ng, Derron A. Alves, Lucas Tirloni, Jennifer M. Anderson, Adriana Marques, Fabiano Oliveira, Shaden Kamhawi, Daniel E. Sonenshine, José M. C. Ribeiro, Mark Hoon, Jesus G. Valenzuela   +27 more
wiley   +1 more source

Effect of fingolimod on platelet count among multiple sclerosis patients

International Journal of Preventive Medicine, 2015
Background: While many studies have previously focused on fingolimod′s effect on immune cells, the effect it has on circulating and local central nervous system platelets (Plts) has not yet been investigated.
Mehrdad Farrokhi, Ali Amani Beni, Masoud Etemadifar, Ali Rezaei, Leah Rivard, Aryan Rafiee Zadeh, Nahid Sedaghat, Milad Ghadimi   +7 more
doaj   +1 more source

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis

Drugs in R&D, 2020
Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases.
Pablo Bascuñana, Luisa Möhle, Mirjam Brackhan, Jens Pahnke   +3 more
doaj   +1 more source

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

PLoS ONE, 2021
ObjectiveTo describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.MethodsAn observational ...
J E Meca-Lallana, C Oreja-Guevara, D Muñoz, J Olascoaga, A Pato, L Ramió-Torrentà, V Meca-Lallana, M A Hernández, M E Marzo, J C Álvarez-Cermeño, A Rodríguez-Antigüedad, X Montalbán, O Fernández, Spanish GILENYA Registry Investigators   +13 more
doaj   +1 more source

Combination Therapy With Fingolimod and Neural Stem Cells Promotes Functional Myelination [PDF]

, 2019
Myelination, which occurs predominantly postnatally and continues throughout life, is important for proper neurologic function of the mammalian central nervous system (CNS).
Ciric, Bogoljub, Li, Xing, Lu, Xin-Yu, Ma, Cun-Gen, Rostami, A. M., Ye, Ze-Qin, Zhang, Guang-Xian, Zhang, Yuan   +7 more
core   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models

Translational Oncology, 2021
Surgery followed by a chemotherapy agent is the first-line treatment for breast cancer patients. Nevertheless, new targets are required for women with triple-negative breast cancer (TNBC) in order to improve the treatment of this aggressive cancer ...
Tristan Rupp, Océane Pelouin, Laurie Genest, Christophe Legrand, Guillaume Froget, Vincent Castagné   +5 more
doaj   +1 more source

Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion [PDF]

, 2017
Neurotransmission and secretion of hormones involve a sequence of protein/lipid interactions with lipid turnover impacting on vesicle trafficking and ultimately fusion of secretory vesicles with the plasma membrane.
A Flašker, A Ruiz, B Balatoni, B Czech, B Davletov, B Rituper, BA Davletov, C Rickman, C Wu, CA Foster, CF Brosnan, D Marsolais, E Connell, E Connell, E Neher, ET Kavalali, ET Kavalali, EV Mosharov, F Darios, F Safarian, J Vargas-Medrano, K Chiba, K Hu, KL Arendt, L Svennerholm, LM Gutierrez, M Holt, M Rupnik, M Schröder, M Stenovec, MD Ward, N Takasugi, N Vardjan, NC Hait, P O’Connor, R Brunkhorst, R Cipriani, R Deogracias, RM Wightman, S Jurado, S Lipovšek, S Rossi, S Trkov, V Brinkmann, V García-Martínez, V García-Martínez, VT Cruz, X He, Y Wei, YA Hannun, YD Fragoso   +50 more
core   +4 more sources